These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7528662)

  • 1. Safety, side effects and patient acceptance of the antiandrogen Casodex in the treatment of benign prostatic hyperplasia.
    Eri LM; Tveter KJ
    Eur Urol; 1994; 26(3):219-26. PubMed ID: 7528662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators.
    Tyrrell CJ
    Eur Urol; 1994; 26 Suppl 1():15-9. PubMed ID: 7537664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia.
    Eri LM; Tveter KJ
    J Urol; 1993 Jul; 150(1):90-4. PubMed ID: 7685428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia.
    Strutt KL; Blackledge GR; Kennealey GT
    J Urol; 1994 May; 151(5):1355-6. PubMed ID: 7512665
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of the nonsteroidal antiandrogen Casodex on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia.
    Eri LM; Urdal P
    Eur Urol; 1995; 27(4):274-9. PubMed ID: 7544732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical progress with a new antiandrogen, Casodex (bicalutamide).
    Blackledge GR
    Eur Urol; 1996; 29 Suppl 2():96-104. PubMed ID: 8717470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical profile of a new non-steroidal antiandrogen.
    Mahler C; Denis L
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):921-4. PubMed ID: 2126736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer.
    Verhelst J; Denis L; Van Vliet P; Van Poppel H; Braeckman J; Van Cangh P; Mattelaer J; D'Hulster D; Mahler C
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):525-30. PubMed ID: 7525125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group.
    Tyrrell CJ; Denis L; Newling D; Soloway M; Channer K; Cockshott ID
    Eur Urol; 1998; 33(1):39-53. PubMed ID: 9471040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Monitoring of erection function in patients with prostatic carcinoma treated with Casodex].
    Migliari R; Muscas G; Melis M; Garau M; Sorgia M; Scarpa RM; Usai E
    Arch Ital Urol Nefrol Androl; 1991 Mar; 63(1):155-61. PubMed ID: 1830408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.
    Tyrrell CJ; Kaisary AV; Iversen P; Anderson JB; Baert L; Tammela T; Chamberlain M; Webster A; Blackledge G
    Eur Urol; 1998; 33(5):447-56. PubMed ID: 9643663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects on the endocrine system of long-term treatment with the non-steroidal anti-androgen Casodex in patients with benign prostatic hyperplasia.
    Eri LM; Haug E; Tveter KJ
    Br J Urol; 1995 Mar; 75(3):335-40. PubMed ID: 7537602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer.
    Blackledge GR; Cockshott ID; Furr BJ
    Eur Urol; 1997; 31 Suppl 2():30-9. PubMed ID: 9074908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of Casodex in patients with advanced prostate cancer. International Casodex Study Group.
    Lunglmayr G
    Anticancer Drugs; 1995 Aug; 6(4):508-13. PubMed ID: 7579554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current clinical studies with a new nonsteroidal antiandrogen, Casodex.
    Kaisary AV
    Prostate Suppl; 1994; 5():27-33. PubMed ID: 8172713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Casodex on sleep-related erections in patients with advanced prostate cancer.
    Migliari R; Muscas G; Usai E
    J Urol; 1992 Aug; 148(2 Pt 1):338-41. PubMed ID: 1378907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma.
    Kennealey GT; Furr BJ
    Urol Clin North Am; 1991 Feb; 18(1):99-110. PubMed ID: 1992575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Casodex: a pure non-steroidal anti-androgen used as monotherapy in advanced prostate cancer.
    Tyrrell CJ
    Prostate Suppl; 1992; 4():97-104. PubMed ID: 1574464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update of monotherapy trials with the new anti-androgen, Casodex (ICI 176,334). International Casodex Investigators.
    Iversen P
    Eur Urol; 1994; 26 Suppl 1():5-9. PubMed ID: 7737258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group.
    Iversen P; Tveter K; Varenhorst E
    Scand J Urol Nephrol; 1996 Apr; 30(2):93-8. PubMed ID: 8738052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.